OCCIDENT’s End-of-Year Message
As Science Investor, we build bridges of various kinds, overcoming challenges and bridging differences, thus connecting different worlds and perspectives.
News
OCCIDENT’s Annual Review and Christmas dinner
The OCCIDENT Team reviews the past eventful year and tunes in to Christmas. And at the same time, we are looking forward to the new opportunities that await us in the new year.
Tubulis enters into collaboration with Gilead Sciences
The agreement, valued at up to $415 million, combines Gilead's long-standing expertise with Tubulis' innovative technology to advance ADC treatment for solid tumors.
Thermosome presents encouraging first clinical data
Phase I Trial data show safety and potential efficacy in heavily pre-treated soft tissue sarcoma patients. In 4 out of 6 patients, the disease remained stable per RECIST.
OCCIDENT is part of the Helmholtz Enterprise Jury
OCCIDENT as a science investor is proud to work with the German Helmholtz Association to help turn innovative science into great start-ups.
OCCIDENT celebrates 10 years of supporting young talent through CO-OPERAID
OCCIDENT's long-term partnership with CO-OPERAID empowers youth through education, transforming lives and communities in developing nations.
OCCIDENT welcomes the Venture Leaders Cleantech 2024
For the fourth year in a row, we were able to see 10 exciting start-up pitches and spend an inspiring networking evening.
ReCatalyst is celebrating major achievements
Our portfolio company ReCatalyst reaches significant product milestones and signs a memorandum of understanding with a Membrane Electrode Assembly producer.
Initial Investment in Lymphatica
OCCIDENT participates in the € 17.9 million Series B funding round of Lausanne-based Lymphatica Medtech that develops novel treatment options for patients suffering from lymphedema.